Christopher Still, DO
Internal Medicine · Danville, PANPI 1710935739
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $312,187 of the $441,841 with a category attached, or 70.7%. Novo Nordisk accounts for 64.7% of it on its own, with 11 other manufacturers making up the rest. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $1004.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$286K
- Lilly USA, LLC$99K
- Boehringer Ingelheim$25K
- Currax Pharmaceuticals LLC$11K
- Medical Device Business Services, Inc.$8K
- Covidien LP$4K
- plus $8K from 6 others
Across 983 payments — averaging $6791.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rhythm Pharmaceuticals, Inc.$2.4M
- Regeneron$1.4M
- Ethicon Endo-surgery Inc.$1.3M
- Medical Device Business Services, Inc.$813K
- Novo Nordisk$294K
- Novo Nordisk AS$245K
- plus $239K from 1 others
What the payments were for
- Consulting fees$77,98518%
- Speaking & faculty fees$312,18771%
- Travel & lodging$42,74810%
- Food & beverage$8,9212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 258 | $286,047 |
| Lilly USA, LLC | 106 | $99,304 |
| Boehringer Ingelheim | 22 | $25,449 |
| Currax Pharmaceuticals LLC | 9 | $11,316 |
| Medical Device Business Services, Inc. | 9 | $8,233 |
| Covidien LP | 2 | $3,850 |
| Regeneron | 4 | $2,500 |
| Novo Nordisk AS | 1 | $1,875 |
| Johnson & Johnson(2 entities) | 6 | $1,696 |
| Eli Lilly | 21 | $1,519 |
| Baxter Healthcare | 1 | $40 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$183,209
- ZEPBOUND$89,887
- Wegovy$65,988
- CONTRAVE$11,303
- ECHELON FLEX Stapler$5,306
- HARMONIC Product Family$4,702
- Sonicision$3,850
- ECHELON ENDOPATH Stapler$3,100
- ENSEAL Product Family$3,100
- STRATAFIX$2,516
- EVICEL Fibrin Sealant (Human)$1,602
How this compares
$441,841 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $153,806 |
| Naltrexone Hcl | 33 | $2,294 |
| Famotidine | 48 | $726 |
| Ondansetron HclOndansetron Hcl/Pf | 53 | $712 |
| Potassium Chloride | 49 | $386 |
| Topiramate | 28 | $269 |
| Metformin Hcl ErMetformin Hcl | 22 | $210 |
| Bupropion Hcl SrBupropion Hcl | 15 | $202 |
| Metformin Hcl | 36 | $195 |
| Hydrochlorothiazide | 13 | $13 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $286,047 | $153,806123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Danville
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
- Gerald BishopErie$307K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.